SG11201404543UA - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents

Pluripotent germ layer origin antigen presenting cancer vaccine

Info

Publication number
SG11201404543UA
SG11201404543UA SG11201404543UA SG11201404543UA SG11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA
Authority
SG
Singapore
Prior art keywords
antigen presenting
cancer vaccine
germ layer
pluripotent germ
presenting cancer
Prior art date
Application number
SG11201404543UA
Inventor
Andrew Cornforth
Robert Dillman
Original Assignee
California Stem Cell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cell Inc filed Critical California Stem Cell Inc
Publication of SG11201404543UA publication Critical patent/SG11201404543UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201404543UA 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine SG11201404543UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594304P 2012-02-02 2012-02-02
PCT/US2013/024123 WO2013116505A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Publications (1)

Publication Number Publication Date
SG11201404543UA true SG11201404543UA (en) 2014-08-28

Family

ID=48905824

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404543UA SG11201404543UA (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Country Status (13)

Country Link
US (1) US20150064217A1 (en)
EP (1) EP2809775B1 (en)
JP (1) JP2015506698A (en)
KR (1) KR20140143361A (en)
CN (1) CN104540937A (en)
AU (1) AU2013215116A1 (en)
CA (1) CA2863653A1 (en)
GB (1) GB2512558A (en)
HK (2) HK1202432A1 (en)
IL (1) IL233928A0 (en)
NZ (1) NZ628292A (en)
SG (1) SG11201404543UA (en)
WO (2) WO2013116541A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599528B (en) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 The preparation method of human dendritic cell vaccine
WO2018070069A1 (en) * 2016-10-11 2018-04-19 サイトリミック株式会社 Medicine
CN110198717A (en) * 2017-01-11 2019-09-03 国立研究开发法人国立癌症研究中心 Immunization therapy medicine
KR20190115080A (en) * 2017-02-17 2019-10-10 에이비타 바이오메디컬, 인크. Methods for Promoting Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapy Products Using Modified Tumor Cells and Modified Dendritic Cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
KR20050027163A (en) * 2001-09-06 2005-03-17 노쓰웨스트 바이오써라퓨틱스, 인크. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
JP5623004B2 (en) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Dendritic cells loaded with heat shocked melanoma cell bodies
WO2007016340A2 (en) * 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
US8097256B2 (en) * 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Also Published As

Publication number Publication date
GB201414403D0 (en) 2014-10-01
EP2809775A4 (en) 2015-07-01
HK1209455A1 (en) 2016-04-01
KR20140143361A (en) 2014-12-16
CN104540937A (en) 2015-04-22
US20150064217A1 (en) 2015-03-05
CA2863653A1 (en) 2013-08-08
JP2015506698A (en) 2015-03-05
EP2809775A1 (en) 2014-12-10
IL233928A0 (en) 2014-09-30
WO2013116541A1 (en) 2013-08-08
EP2809775B1 (en) 2018-06-13
WO2013116505A1 (en) 2013-08-08
AU2013215116A1 (en) 2014-08-21
NZ628292A (en) 2016-09-30
HK1202432A1 (en) 2015-10-02
GB2512558A (en) 2014-10-01

Similar Documents

Publication Publication Date Title
HK1207962A1 (en) Mycobacterial antigen vaccine
HK1207967A1 (en) Vaccine
HK1204302A1 (en) Compositions and methods for cancer immunotherapy
EP2714073A4 (en) In situ antigen-generating cancer vaccine
LT3892295T (en) Individualized vaccines for cancer
EP2876161A4 (en) Vaccine
GB201223386D0 (en) Vaccine
EP2868325A4 (en) Transdermal cancer antigen peptide preparation
SG11201500396TA (en) Tumor vaccination
HK1201176A1 (en) Antigen presenting cancer vaccine
GB201003293D0 (en) Cancer vaccine
HK1209455A1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
HK1202070A1 (en) Vaccine for tumor immunotherapy
EP2869828A4 (en) Vault immunotherapy
ZA201407309B (en) Antigens and antigen combinations
ME03498B (en) Individualized vaccines for cancer
GB201202090D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201217321D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201207383D0 (en) Antigens and antigen combinations
GB201207385D0 (en) Antigens and antigen combinations
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations